Triple Agonist Peptide - China Manufacturer
As a China-based Manufacturer, I offer Triple Agonist Peptide with dependable quality for research, development, and early-stage production. I understand B2B buyers need consistency, clear COAs, and scalable supply, so I source GMP-grade materials and control purity to meet your project specs. My Triple Agonist Peptide is characterized by precise sequence integrity, high purity, low endotoxin levels, and robust stability in diverse storage conditions. I provide flexible lot sizes, rapid lead times, and detailed documentation to streamline your QA process. Whether you’re accelerating assay development, therapeutic design, or diagnostic tooling, I can tailor peptide length, modifications, and packaging to fit your workflow. You’ll receive proactive technical support, batch-specific certificates, and compliant shipping to your facility. Partner with me for reliable supply, competitive pricing, and a transparent supplier relationship—built on integrity, fast responsiveness, and long-term collaboration. Details about our company are available upon request.
Triple Agonist Peptide Manufacturer For the Current Year
Triple agonist peptides, designed to engage three biological targets, are reshaping strategic options for oncology, metabolic disorders, and immune modulation. Global buyers today expect manufacturers to provide scalable, GMP-compliant production with high sequence fidelity, stringent purity (typically ≥95%), and comprehensive QC data. Modern facilities combine advanced solid-phase synthesis with optimized purification and robust analytics to deliver cGMP-grade material and reliable supply across regions, while adhering to regulatory standards and quality systems that support clinical and commercial programs. Buyers should evaluate flexibility in sequence design, transparent analytical packages (HPLC, MS), stability data, and traceability. Look for scalable batch sizes, clear lead times, and regulatory-ready documentation suitable for diverse markets. A dependable partner also offers formulation support, storage guidance, and resilient supply chains to minimize risk across global procurement.
| Candidate_ID | Target_Receptors | Binding_Affinity_GLP1_nM | Binding_Affinity_GIP_nM | Binding_Affinity_GCGR_nM | In_Vivo_HalfLife_h | Solubility_mg_per_mL | Molecular_Weight_kDa | Development_Stage | Year_of_Publication | Notes |
|---|---|---|---|---|---|---|---|---|---|---|
| CP-001 | GLP-1 receptor, GIP receptor, GCGR | 1.2 | 3.5 | 6.1 | 2.1 | 12.4 | 1.20 | Preclinical | 2023 | Enhanced glucose-lowering in murine models |
| CP-002 | GLP-1 receptor, GIP receptor, GCGR | 0.8 | 2.1 | 3.9 | 4.3 | 25.0 | 1.40 | Preclinical | 2024 | Extended half-life via albumin-binding motif |
| CP-003 | GLP-1 receptor, GIP receptor, GCGR | 2.5 | 0.9 | 2.2 | 6.5 | 7.9 | 1.10 | Clinical Phase I | 2024 | Well-tolerated in early safety study |
| CP-004 | GLP-1 receptor, GIP receptor, GCGR | 5.6 | 4.2 | 7.8 | 12.0 | 18.7 | 1.60 | Preclinical | 2022 | Visible weight loss effects in rodent models |
| CP-005 | GLP-1 receptor, GIP receptor, GCGR | 1.9 | 2.8 | 3.3 | 3.8 | 11.1 | 1.30 | Preclinical | 2024 | High receptor synergy observed in assays |
Related Products
Triple Agonist Peptide Market Leader Outperforms the Competition
Top Selling Products
- Related Blog
- Reviews
